To verify the effect of targeting STX17-DT in combination with axitinib therapy in vivo, we generated five patient-derived tumor xenograft (PDX) models of ccRCC (Supplementary Table 3). The gene discussed is STX17; the disease is nonpapillary renal cell carcinoma.